Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

LONDON, February 6, 2013 /PRNewswire/ --

Pharma stocks performed fairly well lately. However, the main concern for all the major companies was related to the patent expiry of their blockbuster drugs. Amgen Inc. (NASDAQ: AMGN) is about to lose its patent exclusivity for its cancer drug Neupogen. However, the sector is also witnessing good merger and acquisition activities, where big players are acquiring smaller companies in order to make up the losses sustained through patent expirations. Smaller biotech companies are also betting big on developing drugs for various cancers, though the prospects do not look so bright. StockCall analysts have released their latest round of technical research on Amgen and Peregrine. This free research can be accessed by signing up now at

http://www.stockcall.com/registration

Amgen Provides Optimistic Projections

Amgen recently reported positive results for the fourth quarter. Its revenue grew 11.25 percent to $4.42 billion while its adjusted net income stood at $1.40 per share, beating consensus estimate of $1.39 per share in quarterly net income. Amgen expects its FY 2013 adjusted earnings to be in the range of $6.85 and $7.15 per share, while revenue is likely to be in the range of $17.8 billion and $18.2 billion, in comparison to $17.3 billion in revenue it earned for FY2012. Thus, while the company is likely to report better results, but the rate of growth is likely to be a little muted. However, Amgen surpassed consensus estimates for the projections. Register today and read our free technical report on Amgen at

http://www.StockCall.com/AMGN020613.pdf

The company also successfully conducted phase 3 of its cancer drug Neulasta. Amgen draws a big chunk
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... financial results for the fiscal third quarter 2015 after ... The Company will also host a conference ... 9:00 a.m. Central Time (10:00 a.m. Eastern Time). Investors ...
(Date:8/3/2015)... MINNEAPOLIS , Aug. 3, 2015 /PRNewswire/ ... a significant shareholder and will become the exclusive ... for cardiology-related diagnostic and monitoring offerings. ... for Preventice Solutions," said Jon Otterstatter , ... Preventice Solutions.  "We are thrilled to partner with ...
(Date:8/3/2015)... Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest independent ... 30, 2015. All comparisons, unless otherwise noted, are to the ... 2015 Highlights include: , Revenue of $808 million, ... prescriptions dispensed of 234,000, an increase of 19% , ... of $22.7 million, an increase of 287% or $16.8 million ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... Nobilon, the human vaccine business unit of ... that it has reached an important milestone with the ... 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) ... the three attenuated Influenza viruses recommended by the World ...
... Texas, March 13 At the Health Industries Council ... and professor of public health and behavioral sciences at ... School of Public Health, announced new findings that ... Specifically, unemployment and reduced spending on health care ...
Cached Medicine Technology:Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 2Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 3Unemployment, Health Care Spending Affect Mortality 2
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... ... 03, 2015 , ... Kantor & Kantor, LLP announced today ... client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement Income ... treatment for bulimia, depression and other mental health problems. , According to the ...
(Date:8/3/2015)... ... 03, 2015 , ... Pitt Researchers to Monitor Resistance to ... School of Medicine are leading a five-year, $5 million initiative to monitor drug ... A cooperative agreement awarded by the U.S. Agency for International Development (USAID), will ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... developed a new method that advocates the use of ... ,D. Karunagaran, a professor at the department of ... Madras, and Suby Oommen, a PhD student at the ... working on garlic-based components and their effects on cancer ...
... Pakistani government has strictly warned health officials in Islamabad not ... thirty five deaths// following viral dengue fever in ... department of Health divulged to media that the health ... nurse from sharing or divulging any news related to the ...
... issue of Developmental Psychology has explained the immense benefit ... // which supports reading development and also introduces them ... highly beneficial in promoting learning in the children. ... own dozens of children's picture books and spend approximately ...
... dog' policy and check rising cases of rabies, the police will ... dogs from Nov 16. // ,The campaign aims to ... licence for their dogs, local police said. ,In the ... an increase of 29.69 percent over the same period last year. ...
... most of the flu shot supply had been delivered by ... the state's total order has been received, while the rest ... will be stocked that includes privately purchased flu vaccine. ... Prevention revealed that this flu season over 115 million doses ...
... body's immune system can be used as an effective weapon ... immune system was enhanced by drugs lived longer and their ... in the U.S. were able to improvise the immune system's ... a conference on cancer research at Prague. ,Nearly ...
Cached Medicine News:Health News:Garlic compound may help treat cancer 2Health News:Picture Book Reading Helps Toddlers Grasp Complex Actions 2Health News:New Treatment For Skin Cancer Using Body's own Immune System 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: